GYRE
Gyre Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Gyre Therapeutics has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+4.22%
vs ±65.8% implied · ×0.06
shaded = implied · ▲▼ = realized
Gyre Therapeutics, Inc.
4.64
SentenceDistributors are our direct customers, and sales to distributors accounted for 100.0% of the revenue from each of ETUARY®, Etorel® and Contiva®.
basisGYRE FY2025 revenue $117M
GYRE 10-Kaccession 0001193125-26-106251
SentenceThrough in-house R&D efforts and collaborative arrangements with GNI Group, Ltd. ("GNI Japan"), we have developed, in addition to ETUARY®, a pipeline of pharmaceutical product candidates at various phases of clinical development, including Hydronidone, F528, F230 and F573.
GYRE 10-Kaccession 0001193125-26-106251
SentenceIn May 2024, Gyre Pharmaceuticals entered into a comprehensive agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. to obtain the drug registration certificate for Etorel® (nintedanib) and become the marketing authorization holder in the PRC.
GYRE 10-Kaccession 0001193125-26-106251
SentenceIn June 2021, Gyre Pharmaceuticals acquired avatrombopag maleate tablets pursuant to a transfer agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd.
GYRE 10-Kaccession 0001193125-26-106251
SentenceThe manufacturing of Hydronidone active pharmaceutical ingredients ("API") and drug product required to support the planned Phase 2 clinical trial will be completed by WuXi STA, located in the PRC.
GYRE 10-Kaccession 0001193125-26-106251
Expected move
No implied move.